These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33589526)

  • 1. Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy.
    Muñoz NM; Williams M; Dixon K; Dupuis C; McWatters A; Avritscher R; Manrique SZ; McHugh K; Murthy R; Tam A; Naing A; Patel SP; Leach D; Hartgerink JD; Young S; Prakash P; Hwu P; Sheth RA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
    Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity.
    Rossi M; Carboni S; Di Berardino-Besson W; Riva E; Santiago-Raber ML; Belnoue E; Derouazi M
    Front Immunol; 2021; 12():695056. PubMed ID: 34276686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration.
    Li K; Wang J; Zhang R; Zhou J; Espinoza B; Niu N; Wang J; Jurcak N; Rozich N; Osipov A; Henderson M; Funes V; Lyman M; Blair AB; Herbst B; He M; Yuan J; Trafton D; Yuan C; Wichroski M; Liu X; Fu J; Zheng L
    J Hematol Oncol; 2024 Aug; 17(1):62. PubMed ID: 39113096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thermosensitive Gel-Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197.
    Fakhari A; Nugent S; Elvecrog J; Vasilakos J; Corcoran M; Tilahun A; Siebenaler K; Sun J; Subramony JA; Schwarz A
    J Pharm Sci; 2017 Aug; 106(8):2037-2045. PubMed ID: 28456734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site.
    Ohkuri T; Kosaka A; Ishibashi K; Kumai T; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Celis E; Kobayashi H
    Cancer Immunol Immunother; 2017 Jun; 66(6):705-716. PubMed ID: 28243692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral Administration of Thermosensitive Hydrogel Co-Loaded with Norcantharidin Nanoparticles and Doxorubicin for the Treatment of Hepatocellular Carcinoma.
    Gao B; Luo J; Liu Y; Su S; Fu S; Yang X; Li B
    Int J Nanomedicine; 2021; 16():4073-4085. PubMed ID: 34163160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STINGel: Controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy.
    Leach DG; Dharmaraj N; Piotrowski SL; Lopez-Silva TL; Lei YL; Sikora AG; Young S; Hartgerink JD
    Biomaterials; 2018 May; 163():67-75. PubMed ID: 29454236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral injection of gels containing losartan microspheres and (PLG-g-mPEG)-cisplatin nanoparticles improves drug penetration, retention and anti-tumor activity.
    Yu M; Zhang C; Tang Z; Tang X; Xu H
    Cancer Lett; 2019 Feb; 442():396-408. PubMed ID: 30439541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ROS-responsive thermosensitive polypeptide hydrogels for localized drug delivery and improved tumor chemoimmunotherapy.
    Li F; Ding J; Li Z; Rong Y; He C; Chen X
    Biomater Sci; 2024 Jun; 12(12):3100-3111. PubMed ID: 38712522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy.
    Wilson DR; Sen R; Sunshine JC; Pardoll DM; Green JJ; Kim YJ
    Nanomedicine; 2018 Feb; 14(2):237-246. PubMed ID: 29127039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer.
    Sheth RA; Murthy R; Hong DS; Patel S; Overman MJ; Diab A; Hwu P; Tam A
    JAMA Netw Open; 2020 Jul; 3(7):e207911. PubMed ID: 32725245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapeutic effects of intratumoral nanoplexed poly I:C.
    Aznar MA; Planelles L; Perez-Olivares M; Molina C; Garasa S; Etxeberría I; Perez G; Rodriguez I; Bolaños E; Lopez-Casas P; Rodriguez-Ruiz ME; Perez-Gracia JL; Marquez-Rodas I; Teijeira A; Quintero M; Melero I
    J Immunother Cancer; 2019 May; 7(1):116. PubMed ID: 31046839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
    Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
    Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors.
    Rettman P; Blunt MD; Fulton RJ; Vallejo AF; Bastidas-Legarda LY; España-Serrano L; Polak ME; Al-Shamkhani A; Retiere C; Khakoo SI
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STING agonist-based hydrogel enhances immune activation in synergy with radiofrequency ablation for hepatocellular carcinoma treatment.
    Ao F; Li X; Tan Y; Jiang Z; Yang F; Guo J; Zhu Q; Chen Z; Zhou B; Zhang K; Li D
    J Control Release; 2024 May; 369():296-308. PubMed ID: 38301925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Ablation and Therapeutic Immunity Induction by an Injectable Peptide Hydrogel.
    Jin H; Wan C; Zou Z; Zhao G; Zhang L; Geng Y; Chen T; Huang A; Jiang F; Feng JP; Lovell JF; Chen J; Wu G; Yang K
    ACS Nano; 2018 Apr; 12(4):3295-3310. PubMed ID: 29558107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy.
    Alvarez M; Molina C; De Andrea CE; Fernandez-Sendin M; Villalba M; Gonzalez-Gomariz J; Ochoa MC; Teijeira A; Glez-Vaz J; Aranda F; Sanmamed MF; Rodriguez-Ruiz ME; Fan X; Shen WH; Berraondo P; Quintero M; Melero I
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.